Galicaftor is under clinical development by Sionna Therapeutics and currently in Phase II for Cystic Fibrosis.

This article gives an overview of the medications for cystic fibrosis. Cystic fibrosis transmembrane conductance regulator (CFTR) modulators are a class of medications that help improve the ...

As Vertex Pharmaceuticals reels from a painful trial readout for its pain candidate suzetrigine, the Boston biotech has ...

combined groups: −5.4 mV (p < 0.001) CF = cystic fibrosis; FEV 1 = forced expiratory volume in 1 second. The classes of cystic fibrosis transmembrane conductance regulator (CFTR) mutations.

Vertex has won two cystic fibrosis approvals from the FDA, but the agency included high-level safety warnings.

(RTTNews) - Vertex Pharmaceuticals Inc. (VRTX) Friday announced that the U.S. Food and Drug Administration (FDA) has approved Alyftrek for treatment of cystic fibrosis.

Alyftrek is Vertex's fifth CFTR modulator to secure FDA approval. It is also under regulatory review in the European Union, the United Kingdom, Canada, Switzerland, Australia and New Zealand. Write to ...

The medicine, called trikafta, can treat cystic fibrosis patients who have at least one F508del mutation in the transmembrane conductance regulator gene or a mutation that is responsive to trikafta ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved ALYFTREK (vanzacaftor/tezacaftor ...

CF is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. An estimated 105,000 people have been diagnosed with CF across 94 countries, according to the CF ...

CF is caused by a mutation in the gene for the protein cystic fibrosis transmembrane conductance regulator (CFTR). This gene is required to regulate the components of sweat, digestive juices ...

- In head-to-head clinical trials, ALYFTREK was non-inferior on ppFEV 1 and further decreased sweat chloride compared to TRIKAFTA ® - BOSTON, December 20, 2024--(BUSINESS WIRE)--Vertex ...